Pulmonary surfactant formulations and methods for promoting mucus clearance
Methods and compositions to enhance mucus clearance and to treat pulmonary lung disorders such as cystic fibrosis are disclosed. The methods utilize compositions including synthetic pulmonary surfactants having one or more phospholipids and a synthetic polypeptide, administered alone or combined with hyperosmotic agents, to patients in an amount effective to enhance mucus clearance.
1. A method for promoting mucus clearance in a patient with a pulmonary condition characterized by excessive mucus secretion or impaired mucus clearance, wherein the pulmonary condition is cystic fibrosis, bronchiectasis, primary or secondary ciliary diskinesia, COPD, or sinusitis, the method comprising administering to the patient at least one osmotically active agent and at least one synthetic pulmonary surfactant comprising one or more phospholipids and a synthetic polypeptide comprising at least 10 amino acid residues and no more than about 60 amino acid residues, said polypeptide including a sequence having alternating hydrophobic and hydrophilic amino acid residue regions represented by the formula
(Z a U b ) c Zd,
wherein:
Z is a hydrophilic amino acid residue independently selected from the group consisting of R and K;
U is a hydrophobic amino acid residue independently selected from the group consisting of L and C;
a is 1 or 2;
b has an average value of about 3 to about 8;
c is 1 to 10; and
d is 0 to 2,
wherein the synthetic polypeptide is admixed with the one or more phospholipids and wherein the at least one synthetic pulmonary surfactant has a surfactant activity greater than the surfactant activity of the one or more phospholipids alone, and wherein the at least one synthetic pulmonary surfactant is formulated to provide the patient with a lung dose of between about 20 and about 200 mg total phospholipid per day, thereby promoting the mucus clearance in the patient.
2. The method of claim 1 , wherein the pulmonary surfactant comprises 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol (POPG), palmitic acid (PA) and a peptide having a sequence of KLLLLKLLLLKLLLLKLLLLK (KL4, SEQ ID NO:1).
3. The method of claim 1 , wherein the pulmonary surfactant is administered as a liquid instillate, a liquid aerosol or a dry aerosol.
4. The method of claim 1 , wherein the lung dose is between about 30 and about 150 mg total phospholipid per day.
5. The method of claim 1 , wherein the osmotically active agent is a pharmaceutically acceptable sugar, sugar alcohol or salt.
6. The method of claim 5 , wherein the osmotically active agent is NaCl and is formulated as a saline solution.
7. The method of claim 6 , wherein the saline solution comprises about 0.13 to about 1.2 Osm sodium chloride.
8. A method for promoting mucus clearance in a patient with cystic fibrosis, comprising administering to the patient at least one osmotically active agent and at least one synthetic pulmonary surfactant comprising one or more phospholipids and a synthetic polypeptide comprising at least 10 amino acid residues and no more than about 60 amino acid residues, said polypeptide including a sequence having alternating hydrophobic and hydrophilic amino acid residue regions represented by the formula
(Z a U b ) c Zd,
wherein:
Z is a hydrophilic amino acid residue independently selected from the group consisting of R and K;
U is a hydrophobic amino acid residue independently selected from the group consisting of L and C;
a is 1 or 2;
b has an average value of about 3 to about 8;
c is 1 to 10; and
d is 0 to 2,
wherein the synthetic polypeptide is admixed with the one or more phospholipids and wherein the at least one synthetic pulmonary surfactant has a surfactant activity greater than the surfactant activity of the one or more phospholipids alone, and wherein the at least one synthetic pulmonary surfactant is formulated to provide the patient with a lung dose of between about 20 and about 200 mg total phospholipid per day, thereby promoting the mucus clearance in the patient.
9. The method of claim 8 , wherein the pulmonary surfactant comprises 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol (POPG), palmitic acid (PA) and a peptide having a sequence of KLLLLKLLLLKLLLLKLLLLK (KL4, SEQ ID NO:1).
10. The method of claim 8 , wherein the pulmonary surfactant is administered as a liquid instillate, a liquid aerosol or a dry aerosol.
11. The method of claim 8 , wherein the lung dose is between about 30 and about 150 mg total phospholipid per day.
12. The method of claim 8 , wherein the osmotically active agent is a pharmaceutically acceptable sugar, sugar alcohol or salt.
13. The method of claim 12 , wherein the osmotically active agent is NaCl and is formulated as a saline solution.
14. The method of claim 13 , wherein the saline solution comprises about 0.13 to about 1.2 Osm sodium chloride.